ClinicalTrials.gg
Active, not recruitingNCT05280548CARATUpdated Jun 24, 2026

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

A Phase 3 interventional study of Venglustat (GZ402671) and Agalsidase alfa in Fabry Disease, sponsored by Sanofi. Active, not recruiting at 54 sites in 19 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies in Fabry Disease by Sanofi — 1 open to participants now, 3 under way, 2 of them phase 3. Fabry Disease · Sanofi.

Enrollment
2nd of 19
104 · median 20
Started
2022
with 1 other
Phase 3
4 of 23
none open now
Registered
20th of 23
by date

Among the 23 studies in Fabry Disease by Sanofi, this one is the 2nd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 3, and was the 20th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

1 of the 23 studies in Fabry Disease by Sanofi is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Fabry Disease by Sanofi, or all of them as a file.
02

Study summary

This is an 18-month, multicenter, randomized, active-control, parallel-group Phase 3 study, in which participants will be randomized to venglustat versus standard of care therapy (agalsidase alfa, agalsidase beta, or migalastat) to evaluate the effect of venglustat on left ventricular mass index (LVMI) in adult participants with Fabry disease and left ventricular hypertrophy.

  • Study visits will take place approximately every 3 to 6 months
  • Participants who complete the randomized period may continue to the long-term extension (LTE) to receive venglustat for up to additional 45 months with the total study duration up to 5.3 years maximum.
Read the detailed description

Randomized period: the total duration will be up to approximately of 20 months (1 month screening 18 months of treatment and a possible follow-up period of 1 month if no participation in the long-term extension period)

Long-term extension period: the total duration will be from minimum 19 months (18 months of treatment and 1 month of follow-up period) to maximum 46 months (45 months of treatment and 1 month of follow-up period). The maximum total study duration is approximately 5.3 years

03

Conditions studied

  • Fabry Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 65 with previously confirmed diagnosis of Fabry disease and a history of clinical symptoms of Fabry disease.
  • Participants may be receiving treatment with agalsidase alfa, agalsidase beta, or migalastat, or may be untreated.
  • Left ventricular hypertrophy.
  • for male or female participants: not pregnant or breastfeeding; no sperm donating for male participant.
  • A signed must be provided prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  • History of , stroke, myocardial infarction, heart failure, major cardiovascular surgery or kidney transplantation.
  • History of seizures currently requiring treatment.
  • Underlying medical condition that may cause or contribute to left ventricular hypertrophy.
  • Asymmetric hypertrophy by cardiac MRI at screening if considered by central reader to be not related to Fabry disease.
  • Advanced cardiac fibrosis, defined as significant late gadolinium enhancement affecting 3 or more segments involving >50% of myocardial thickness on screening cardiac MRI.
  • History of cardiac arrhythmia. Atrial fibrillation that is well controlled on a stable medical regimen for at least 12 months is not an exclusion if the CHA2DS2-VASc score is 0 for males or 1 for females.
  • Estimated \<45 mL/min/1.73m2.
  • Presence of severe depression as measured by Beck's Depression Inventory (BDI)-II >28 and/or a history of an untreated, unstable major affective disorder within 1 year of the screening visit.
  • Patients with , , or infection.
  • Positive SARS-CoV-2 virus test within 2 weeks of enrollment, or COVID-19 requiring hospitalization within 6 months of enrollment.
  • History of drug and/or alcohol abuse.
  • Moderate to severe hepatic impairment.
  • History of or active hepatobiliary disease.
  • Liver enzymes (/aspartate aminotransferase) or total >2 times the .
  • Strong or moderate inducers or inhibitors of cytochrome P450 within 14 days or 5 half-lives, whichever is longer, prior to randomization.
  • Known to undergoing MRI or known to gadolinium-based contrast agents.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Venglustat

    Participants will receive venglustat once daily, orally

    Drug: Venglustat (GZ402671)

  • Active comparator
    Standard of Care Therapy

    Participants will receive a locally approved Fabry therapy at the standard dose and schedule (in accordance with the locally approved prescribing information)

    Drug: Agalsidase alfa · Drug: Agalsidase beta (GZ419828) · Drug: Migalastat

Interventions

06

What researchers measure

Primary outcomes

  1. Slope of left ventricular mass index as measured by cardiac magnetic resonance imaging (MRI) (central reading)

    Time frame: from baseline to 18 months

Secondary outcomes

  1. Slope of estimated glomerular filtration rate (eGFR) as assessed by the chronic kidney disease epidemiology collaboration (CKD-EPI) creatinine equation

    Time frame: from baseline to 18 months

  2. Change in T1 relaxation time, measured by cardiac MRI (central reading)

    Time frame: from baseline to 18 months

  3. Change in global longitudinal strain, measured by echocardiography (central reading)

    Time frame: from baseline to 18 months

  4. Percent Change in tiredness component of FD-PRO

    Time frame: from baseline to 18 months

  5. Percent Change in swelling in lower extremities component of FD-PRO

    Time frame: from baseline to 18 months

  6. Number of participants with adverse event (AE) and serious adverse event (SAE)

    Time frame: from baseline to 18 months

  7. Change in Beck Depression Inventory-II (BDI-II) score

    Time frame: from baseline to 18 months

  8. Change in the lens clarity by ophthalmological examination

    Time frame: from baseline to 18 months

  9. Plasma venglustat concentrations at prespecified visits over the study duration

    Time frame: from baseline to 18 months

07

Study locations

54 sites
  • University of Alabama -The Kirklin Clinic- Site Number : 8400010
    Birmingham, Alabama 35233, United States
  • University of California Los Angeles Medical Center- Site Number : 8400008
    Los Angeles, California 90095, United States
  • Emory University School of Medicine - Atlanta- Site Number : 8400009
    Atlanta, Georgia 30322, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago- Site Number : 8400005
    Chicago, Illinois 60611, United States
  • Maryam Banikazemi, MD- Site Number : 8400001
    Hawthorne, New York 10532, United States
  • Renal Disease Research Institute- Site Number : 8400012
    Dallas, Texas 75204, United States
  • University of Utah Health Hospital- Site Number : 8400006
    Salt Lake City, Utah 84132, United States
  • Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)- Site Number : 8400004
    Fairfax, Virginia 22030, United States
  • Investigational Site Number : 0400001
    Graz, 8036, Austria
  • Investigational Site Number : 1240003
    Calgary, Alberta T2M 0L6, Canada
  • Investigational Site Number : 1240006
    Edmonton, Alberta T6G 2B7, Canada
  • Investigational Site Number : 1240002
    Vancouver, British Columbia V5Z 1M9, Canada
  • Investigational Site Number : 1240005
    Toronto, Ontario M5T 3H7, Canada
  • Investigational Site Number : 1560002
    Beijing, 100034, China
  • Investigational Site Number : 1560005
    Beijing, 100034, China
  • Investigational Site Number : 1560001
    Chengdu, 610041, China
  • Investigational Site Number : 1560007
    Guangzhou, 510080, China
  • Investigational Site Number : 1560003
    Shanghai, 200025, China
  • Investigational Site Number : 2030001
    Prague, 128 08, Czechia
  • Investigational Site Number : 2080001
    Copenhagen, 2100, Denmark
  • Investigational Site Number : 2500001
    Garches, 92380, France
  • Investigational Site Number : 2760003
    Berlin, 10117, Germany
  • Investigational Site Number : 2760004
    Hochheim am Main, 65239, Germany
  • Investigational Site Number : 2760005
    Mainz, 55131, Germany
  • Investigational Site Number : 2760001
    Würzburg, 97080, Germany
  • Investigational Site Number : 3000002
    Athens, 115 27, Greece
  • Investigational Site Number : 3000003
    Athens, 124 62, Greece
  • Investigational Site Number : 3000001
    Heraklion, 711 10, Greece
  • Investigational Site Number : 3800001
    Milan, Lombardy 20122, Italy
  • Investigational Site Number : 3800002
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800003
    Naples, Napoli 80131, Italy
  • Investigational Site Number : 3800004
    Bologna, 40138, Italy
  • Investigational Site Number : 3920006
    Sapporo, Hokkaido 060-8648, Japan
  • Investigational Site Number : 3920007
    Kagoshima, Kagoshima-ken 890-0064, Japan
  • Investigational Site Number : 3920003
    Kagoshima, Kagoshima-ken 890-8520, Japan
  • Investigational Site Number : 3920005
    Kawasaki, Kanagawa 215-0026, Japan
  • Investigational Site Number : 3920002
    Sendai, Miyagi 980-8574, Japan
  • Investigational Site Number : 3920004
    Fukuoka, 814-0180, Japan
  • Investigational Site Number : 3920001
    Tokyo, 105-8461, Japan
  • Investigational Site Number : 5280001
    Amsterdam, 1105 AZ, Netherlands
  • Investigational Site Number : 5780001
    Bergen, 5021, Norway
  • Investigational Site Number : 6160003
    Lodz, Lódzkie 02-213, Poland
  • Investigational Site Number : 6160001
    Krakow, 31-202, Poland
  • Investigational Site Number : 4100002
    Yangsan, Gyeongsangnam-do 50612, South Korea
  • Investigational Site Number : 4100001
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 7240002
    Madrid, Madrid, Comunidad de 28007, Spain
  • Investigational Site Number : 7240003
    Alicante, 03010, Spain
  • Investigational Site Number : 7240001
    Pontevedra, 36312, Spain
  • Investigational Site Number : 1580003
    Taichung, 407, Taiwan
  • Investigational Site Number : 1580001
    Taipei, 104, Taiwan
  • Investigational Site Number : 7920001
    Ankara, 06560, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Istanbul, 34098, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    İzmit, 41000, Turkey (Türkiye)
  • Investigational Site Number : 8260001
    London, London, City of NW3 2QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in May 2026, 48 months.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2022
First posted
Mar 15, 2022
StartActual
May 3, 2022
Primary completionActual
May 22, 2026
CompletionEst.
Dec 6, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05280548
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
May 3, 2022
Primary completion
May 22, 2026
Completion
Dec 6, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Clinical Sciences & Operations Clinical Sciences and Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venglustat

Start the discussion